FundaMental Pharma

Focus: FundaMental Pharma is a newly founded (2023) German biotech focused on small molecule inhibitors targeting neurodegenerative diseases. As a public-stage company with no disclosed revenue or pipeline data, positioning and market scale remain unclear.

Neurology

Profile data last refreshed 20h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About FundaMental Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow FundaMental Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

11 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Stem Cell Transplantation

Spinal Cord Injury

N/A

Clinical Trials (1)

NCT01325103Autologous Bone Marrow Stem Cell Transplantation in Patients With Spinal Cord Injury

N/A

Help build intelligence for FundaMental Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to build neurology franchise in growing neurodegenerative disease space with unmet medical needs
Located in Heidelberg, Germany—a biotech hub with strong academic and pharma ecosystems
Ground-floor opportunity at a publicly listed company with capital access from day one

Watch Out For

Zero active job openings reported—company not currently hiring, raising questions about capital or strategic direction
No disclosed pipeline, clinical trials, or products—inability to assess science quality, competitive positioning, or probability of success
Founded in 2023 with no published financial data, revenue, or funding transparency—extreme execution risk and unknown runway

Generated by Claude from FundaMental Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Epigenorm Antivir

Osteoarthritis

N/A

Clinical Trials (1)

NCT03540186Epigenorm Antivir Combined With Acupuncture for the Treatment of Osteoarthritis Patients Who Are Overweight or Obese

N/A

Transcranial alternating current stimulation

Alzheimer Disease

N/A

Clinical Trials (1)

NCT0674086440 Hz Transcranial Alternating Current Stimulation for Inducing Gamma Oscillations

N/A